Business Wire

GLOBAL-SWITCH

Share
Global Switch Expands Its European Footprint as Construction Begins at its Amsterdam Data Centre Campus

Global Switch, a leading owner, operator and developer of large scale network dense, carrier and cloud neutral multi-tenanted data centres in Europe and Asia-Pacific has announced that in response to growing demand construction has started on the first stage of a new data centre in Amsterdam.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200624005069/en/

The 32,000 sq m data centre, Global Switch Amsterdam East, will be built immediately adjacent to the existing Amsterdam West facility located in the Slotervaart/Overtoomseveld district, close to the main Dutch cable infrastructure, the financial district and city centre. Global Switch Amsterdam is the only multi-tenant provider in the city with a dedicated mains supply, and once all stages of the new data centre are complete, the utility power supply capacity will increase by 40MVA, bringing the campus total to 72MVA supplied at 50kV.

In contrast to the recent moratorium on granting new data centre planning consents, importantly Global Switch Amsterdam East is a known project with Gemeente Amsterdam (City of Amsterdam) and is not impacted either by the widely announced ‘building stop’ or affected by power availability across the Metropolitan Region of Amsterdam.

Similar to other Global Switch developments, energy efficiency is at the core of the design. Amsterdam East will incorporate the latest technologies such a flooded room cooling design with hot aisle containment allowing flexible IT rack load deployment. The cooling will be generated using a free-cooling water-based cooling system and will allow the heat to be exported to the local community. The data centre will be targeting an annualised design Power Usage Effectiveness (PUE) of less than 1.2 and a BREEAM "Very Good" certification. In addition, as part of Global Switch’s comprehensive Energy Management Programme, customers will be offered 100% green energy.

John Corcoran, CEO Global Switch , said, “We are continuing to see demand for high quality, resilient and energy efficient data centres providing multiple connectivity options particularly from global hyperscale cloud providers looking for highly experienced data centre operators, such as Global Switch, as well as demand from European, US and Asian customers. We are therefore delighted to have now started construction of Global Switch Amsterdam East which will be our fourteenth data centre.”

Jasper Lankhorst, Managing Director Global Switch Amsterdam , said, “It is very exciting to be announcing this substantial addition of world class technical data centre capacity to our Amsterdam campus, particularly at a time when there is a permit stop for new data centre developments in the city and a shortage in power availability in some places of the Amsterdam Metro Area. With the acceleration of the digital economy, Global Switch Amsterdam East will provide an Open Compute Platform ready environment enabling customers to deploy at scale both with speed and cost effectively. As with all our data centres, customers will also benefit from bespoke data centre solutions, as well as a highly resilient and secure space for housing mission critical IT equipment.”

Global Switch Amsterdam West is a core node not just for the Netherlands, but also for Europe and beyond. It is one of the most connected hubs in the country and currently hosts a multitude of global and national telecommunications and cloud providers, AMS-IX and NL-IX as well as a wide range of internet services providers. With direct fibre connections between the two data centres, customers of Amsterdam East will be able to access this connectivity rich environment and will benefit from a wide choice of cloud and network providers as well as direct access to the global IP backbone. The two data centres will provide a total of four diverse entry points and four interconnected Meet Me Rooms ensuring highly resilient connections.

Peter van Burgel, CEO, AMS-IX , said, “We welcome this news by our long-term partner Global Switch. This announcement underlines the importance of the Amsterdam region as one of the largest connectivity hubs in the world and as a desirable climate for digital businesses. It also shows that the digitalisation continues to be a strong, sustainable driver for growth, even in a time when building options are challenging and the economic outlook is uncertain.”

Stijn Grove, Managing Director Dutch Data Center Association (DDA) , said, “The impact of digitalisation on our economy and society is immense. The recent events have only made people more aware that digitalisation is the sustainable way forward to grow our economy. A sound digital foundation is of crucial importance to achieve this. The Metro Region Amsterdam (MRA) is one of the key data hubs in the world and known as the Digital Gateway to Europe. Global Switch’ expansion in the MRA region will strengthen this international position as key data hub even further, and the Dutch and international economy as a whole. We are proud to have Global Switch as a member of the association and congratulate them with their expansion.”

Technical Snapshot

  • Full access to the existing network-dense, low-latency environment with a multitude of carriers and network service providers.
  • Access to peering platforms AMS-IX, NL-IX and all major cloud platforms.
  • Hyperconnected and ideally located adjacent to the main regional and international fibre routes.
  • Built in accordance to the highest operational standards with matching SLA’s.
  • Bespoke solutions with scalable space and power.
  • Open Compute Platform (OCP) facility compliance.
  • Environmentally sustainable targeting a PUE of less than 1.2.
  • Certified ISO9001, 14001, 27001, 50001, OHSAS 18001, AMS-IX, PCI-DSS, ISAE 3402 compliant.

About Global Switch

Global Switch is a leading owner, operator and developer of large-scale, carrier and cloud neutral, multi-customer data centres in Europe and Asia-Pacific. Founded in 1998, Global Switch has a proven business model, demonstrable track record and is the highest credit rated data centre company in the world with investment grade credit ratings from Fitch, Moody’s and Standard & Poor’s.

Global Switch is a vital and strategic partner for customers that require secure and resilient data centre services with scalable capacity and a high-level customer service. The Company's focus is on highly resilient, central, low latency, network dense locations in prime city centre locations and internet hubs close to its customers on the edge of financial and business districts. Global Switch’s data centres operate exclusively in the Tier I markets of Europe and Asia-Pacific to Tier III or higher and currently total around 390,000 sq m (4,200,000 sq ft) of floor space and are occupied by a broad range of customers, global and national, large and small including government organisations, financial institutions, enterprises, global systems integrators, telecommunication carriers, cloud and managed service providers and other hosting businesses.

For more information visit: www.globalswitch.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release

New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release

- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye